Eyenovia Announces $5.14 Million Public Offering
Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a company focused on ophthalmic solutions, has announced its intention to sell 12,850,000 shares of common stock at a price of $0.40 per share.
Details of the Offering
The Offering is anticipated to close shortly, pending the fulfillment of standard closing conditions. Eyenovia is offering all the securities, with Dawson James Securities, Inc. serving as the placement agent. The expected gross proceeds from this Offering are around $5.14 million, before accounting for fees and other expenses.
Planned Use of Proceeds
The net proceeds from the Offering are intended to support commercialization efforts for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, and cover working capital along with general corporate needs.
Securities Registration
The securities being offered are registered under a previously filed shelf registration statement on Form S-3, which became effective on December 23, 2021. The Offering will be conducted solely through a prospectus supplement and the accompanying prospectus.
Contact for Prospectus
For prospectus information, please reach out to Dawson James Securities, Inc., either by phone or email as provided.
About Eyenovia, Inc.
Eyenovia, Inc. specializes in innovative ophthalmic technology, focusing on the commercialization of Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension, as well as advancing the Optejet® device aimed at addressing pediatric progressive myopia. For further details, visit Eyenovia.com.
Contact Information
Eyenovia Contact:
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
Frequently Asked Questions
What is the total amount raised in the public offering?
The public offering is expected to raise approximately $5.14 million.
What will the proceeds from the offering be used for?
The proceeds will fund commercialization activities, a clinical study, and support working capital and general corporate purposes.
Who is acting as the placement agent for the offering?
Dawson James Securities, Inc. is the placement agent for the offering.
When is the closing date for the offering?
The closing date is expected to occur soon, subject to customary closing conditions.
What products are associated with Eyenovia, Inc.?
Eyenovia, Inc. is involved in the commercialization of Mydcombi and Clobetasol Propionate Ophthalmic Suspension, among other initiatives.
